Loading...

Mirati Therapeutics ($MRTX)

Stock Image

MRTX Overview

Mirati Therapeutics, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States.The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development.It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation.Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California. (From: StockAnalysis.com)

MORE ABOUT Mirati Therapeutics

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.